Infliximab-associated lymphoproliferative disorders

International Journal of Hematology

Volumn 81, Issue 4, 2005, Pages 356-357

  Hoshida, Yoshihiko ^a   Yamamoto, Shigeo ^b   Wada, Naoki ^c   Xu, Jing Xian ^a   Sasaki, Toru ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUCILLAMINE; CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; LETTER; LYMPHOPROLIFERATIVE DISEASE; RHEUMATOID ARTHRITIS; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; RISK FACTORS;

EID: 22844443000     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05026     Document Type: Letter

References (8)

1. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
2. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497-502.
3. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A: 1753-1757.
4. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993; 85:307-311.
5. Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:270-271.
6. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943-1949.
7. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-1751.
8. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004;16:254-261.